Puma Biotechnology reported a net product revenue increase for Q2 2023 compared to Q2 2022. The company also achieved positive net income and cash flow during the quarter. They anticipate key milestones over the next 12 months, including initiating a Phase II clinical trial of alisertib in small cell lung cancer.
Net product revenue increased to $51.6 million in Q2 2023, up from $51.3 million in Q2 2022.
GAAP net income was $2.1 million, or $0.05 per basic and diluted share, compared to $9.4 million, or $0.21 per basic and diluted share, for the same period in 2022.
Non-GAAP adjusted net income was $4.6 million, or $0.10 per basic and diluted share, compared to $12.6 million, or $0.28 per basic and diluted share, for the same period in 2022.
Net cash provided by operating activities was $3.3 million, compared to net cash used in operating activities of $13.9 million for the same period in 2022.
Puma Biotechnology provided financial outlook for the third quarter and full year 2023.
Analyze how earnings announcements historically affect stock price performance